Market Indices
Sector Heatmap
AKTS — Aktis Oncology, Inc. Common stock
NasdaqAktis Oncology, Inc. Common stock
- O
- 19.41
- H
- 20.08
- L
- 18.31
- V
- 292.22K
AKTS — Latest News & Headlines
11 StoriesAktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan. - Stock Titan
Aktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan. Stock Titan
Aktis Oncology (AKTS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aktis Oncology (AKTS) Stock Analysis Report | Ratings, Financials & Performance Benzinga
Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6% - Here's What Happened - MarketBeat
Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6% - Here's What Happened MarketBeat
AKTS261016C00030000 Interactive Stock Chart | AKTS Oct 2026 30.000 call Stock - Yahoo Finance
AKTS261016C00030000 Interactive Stock Chart | AKTS Oct 2026 30.000 call Stock Yahoo Finance
A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. - Stock Titan
A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. Stock Titan
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22 - MFI Oversold - dars.gov.et
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22 - MFI Oversold dars.gov.et
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages MarketBeat
AKTS Jan 2027 25.000 call (AKTS270115C00025000) stock price, news, quote and history - au.finance.yahoo.com
AKTS Jan 2027 25.000 call (AKTS270115C00025000) stock price, news, quote and history au.finance.yahoo.com
After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. - Stock Titan
After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. Stock Titan
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22 - Dividend Stock Picks - dars.gov.et
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22 - Dividend Stock Picks dars.gov.et
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Wedbush - MarketBeat
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Wedbush MarketBeat